STOCK TITAN

Exact Sciences (EXAS) Form 144 - Restricted Stock Vesting Sale Notice

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Exact Sciences (EXAS) submitted a Form 144 notifying a proposed sale of 1,485 shares of common stock through Fidelity Brokerage Services LLC (900 Salem Street, Smithfield, RI 02917) with an aggregate market value of $62,399.70. The securities were acquired on 06/12/2025 by restricted stock vesting and payment is listed as compensation. The approximate date of sale is reported as 08/13/2025, and the filing states there were no securities sold during the past three months by the person for whose account the sale is proposed. The filing also discloses total shares outstanding of 189,319,110 and includes the standard representation that the filer does not know of any undisclosed material adverse information.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine insider sale notice for vested compensation; size appears de minimis versus outstanding shares.

The Form 144 reports a proposed sale of 1,485 common shares with an aggregate market value of $62,399.70, acquired by restricted stock vesting on 06/12/2025. The broker is Fidelity Brokerage Services LLC and the approximate sale date is 08/13/2025. The filing states 189,319,110 shares outstanding and notes no sales in the past three months by the reporting person. Impact assessment: not impactful for investors given the small absolute size and routine compensation origin of the shares.

TL;DR: Disclosure follows Rule 144 mechanics and includes the standard representation on material non-public information.

The notice documents that the shares arose from restricted stock vesting and lists payment as compensation, which aligns with routine insider equity compensation practices. The form reiterates the filers representation that they do not know of any undisclosed material adverse information and references Rule 10b5-1 language for plan adoption or trading instructions. From a governance perspective, the filing is a standard compliance disclosure with no indications of governance or disclosure lapses within the provided content.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Exact Sciences' (EXAS) Form 144 report?

The Form 144 reports a proposed sale of 1,485 common shares acquired by restricted stock vesting, with an aggregate market value of $62,399.70.

Who is the broker handling the proposed sale in EXAS Form 144?

The broker listed is Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917.

When were the shares acquired and what is the approximate sale date listed?

The shares were acquired on 06/12/2025 through restricted stock vesting, and the approximate date of sale is 08/13/2025.

Does the filing report any securities sold in the past three months by the filer?

No. The Form 144 explicitly states Nothing to Report for securities sold during the past three months.

How many shares outstanding does the filing disclose?

The filing discloses 189,319,110 shares outstanding.

What does the filer represent about material non-public information?

By signing, the filer represents they do not know of any material adverse information
Exact Sciences Corp

NASDAQ:EXAS

EXAS Rankings

EXAS Latest News

EXAS Latest SEC Filings

EXAS Stock Data

19.24B
186.59M
0.91%
95.62%
3.88%
Diagnostics & Research
Services-medical Laboratories
Link
United States
MADISON